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Abstract
Concerns are often raised regarding potentially adverse effects of antiretroviral therapy (ART) on
health-related quality of life (HRQoL), but there is limited longitudinal data to prove this.
Building on our prior investigation, we examined the impact of ART on HRQoL among HIV-
infected South African women with extensive follow-up in the CAPRISA 002 Acute Infection
Cohort Study. Overall HRQoL and five sub-domains [physical well-being (PWB), emotional well-
being (EWB), functional and global well-being (FGWB), social well-being (SWB) and cognitive
functioning (CF)] were assessed using the Functional Assessment of HIV Infection (FAHI)
instrument. Our analyses comparing FAHI scores between pre-ART (established infection) and
ART phases using paired Wilcoxon signed-rank tests and adjusted mixed-effects regression
models revealed improvements on ART in overall HRQoL, and in PWB, EWB, and SWB, but not
in FGWB and CF. No long-term adverse impact of ART on HRQoL was detected, providing
additional non-biomedical support to early treatment strategies.
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Given the recent breakthroughs in the use of antiretroviral therapy (ART) for HIV
prevention [1] and early treatment [2], there is a growing focus on health-related quality of
life (HRQoL) of individuals living with a life-long disease for which there is currently no
cure. Rapid expansion of ART coverage in South Africa [3], the nation with the highest
burden of HIV infection globally [4], not only means less infections to others through a
reduced individual and community HIV viral load [5, 6], and the benefits of a stronger
immune system to prevent co-infections such as tuberculosis [7], but also provides an
opportunity for individuals to recover or even thrive after the devastating HIV diagnosis.
While reducing viral load and the number of adverse events are key endpoints in ART
studies, the HRQoL outcome is an important indicator of treatment adherence [8, 9] and the
quality of health care delivery [10].
Health-related quality of life, a multi-dimensional and dynamic concept [11], reflects non-
biomedical perspectives of HIV treatment, incorporating important subjective assessments
on wide ranging aspects of individual well-being, including physical, functional, social,
emotional [12] and even spiritual well-being [13] over time. While the scale-up of ART in
KwaZulu-Natal province (KZN) has led to a dramatic increase in life expectancy [14], the
question of long-term HRQoL benefits of ART remains debated and has seldom been
investigated [15]. Few longitudinal studies, and even less recruiting at acute HIV infection,
have been conducted in sub-Saharan Africa. In our previously published report in this
journal [16], we used data from the CAPRISA 002 Acute Infection Study, a cohort study
with extensive follow-up to assess HRQoL of HIV-positive South African women from
acute infection up to ART initiation. Building on these investigations, here, we report on the




The CAPRISA 002 Acute HIV infection study is an ongoing prospective cohort study in
KZN, South Africa. The study [17], which started recruitment in 2004, enrolled a cohort of
HIV uninfected women 18 years and older with the aim to investigate the natural history of
HIV-1 subtype C infection. Study participants were recruited at two sites: Durban, the
largest city in KZN; and Vulindlela, a rural community located north-west of Durban.
Participants were followed up for up to 4 years. Those who acquired HIV were enrolled into
the acute infection stage (Phase II). Women who seroconverted in other CAPRISA
prevention trials [18] also entered the CAPRISA 002 study at Phase II. Acute HIV infection
status of all study participants was established based on a positive HIV antibody status with
a documented HIV negative antibody test within 5 months of study enrollment or by plasma
HIV-1 RNA testing using Amplicor or TaqMan (Roche Diagnostics, Rotkreuz, Switzerland)
prior to seroconversion. Testing procedures of the CAPRISA 002 study have been described
previously in detail [19].
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Participants enrolled in the acute infection study completed a baseline acute infection
assessment immediately after HIV diagnosis and were then followed-up for a maximum of 9
years at the time of our analysis. The follow-up assessment phase was classified as follows:
acute infection (Phase II ≤3 months, but excluding the baseline assessment), early infection
(Phase III >3–12 months), established infection (Phase IV >12 months post-enrolment) and
on ART (Phase V). Fifty-one of 160 participants initiated ART (referred to hereafter as the
ART cohort) according to the South African Adult HIV Treatment Guidelines [20]. All
participants received reimbursement for their time and travel expense for each assessment.
Following diagnosis, post-HIV/sexually transmitted infection risk-reduction counselling, as
well as ART treatment education, was available to study participants. Condoms were
provided on request, and those requiring clinical care received it at the CAPRISA clinical
research site, or at a specialist treatment centre where necessary. The Biomedical Research
Ethics Committee of the University of KwaZulu-Natal approved the study.
Measures
The outcome data were obtained by trained research nurses throughout the study. The
Functional Assessment of HIV Infection (FAHI) instrument was used to measure self-
reported HRQoL, and was assessed at baseline, month three and bi-annually. The FAHI was
designed to assess HRQoL of individuals living with HIV/AIDS and its reliability and
validity has been established [21, 22]. It contains 44 items consisting of five subscales:
physical well-being (PWB) (10 items), emotional well-being (EWB) (10 items), functional
and global well-being (FGWB) (13 items), social well-being (SWB) (8 items), and cognitive
functioning (CF) (3 items). Each item is rated on a 5-point ordinal scale of 0 (not at all) to 4
(very much). Higher FAHI scores reflect greater HRQoL. The Cronbach alpha internal
consistency coefficient for the overall FAHI of the ART cohort was 0.90. Consistency
coefficients for the PWB, EWB, FGWB, SWB, as well as the CF sub-scales were 0.92, 0.80,
0.83, 0.73 and 0.60, respectively.
The main exposure of our study is ART treatment initiation. The date of ART treatment
initiation was obtained through patient chart review (with the permission of the participant).
The study also assessed HIV knowledge, frequency of unprotected sexual practices, and the
number of casual partners, irrespective of marital status at each visit via self-report. For
unprotected sexual practices, risky sexual behavior was dichotomized as either high risk if
the study participant self-reported sex without the use of a condom every time, or no/low
risk for having no sex or sex with a condom being used every time. While we recognize that
many study participants might utilize condoms sometimes, its consistent use is not only part
of recommended practice by the US Center for Disease Control and Prevention [23], but
also shown to substantially reduce HIV infection according to a meta-analysis [24]. In
addition to face-to-face interviews, measurements for body mass index (BMI) and blood
tests, including viral load and CD4, were obtained during the routine clinical assessments at
every study visit.
Data Analysis
Descriptive statistics were used to summarize the demographic characteristics of the ART
cohort. The differences in baseline demographic characteristics between the ART and non-
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ART cohort was assessed using either Chi square (χ2), student’s t test or Wilcoxon rank-sum
test. To assess associations between ART and HRQoL, FAHI scores pre-ART during
established infection were compared to FAHI scores on ART using paired Wilcoxon signed-
rank tests. The proportion of study participants above the minimally important differences
(MID) threshold was calculated using the standard deviation (SD) method [25]. Under this
method, the threshold is half the SD of the baseline score, which is defined as the closest
FAHI score prior to ART initation in our study context. The last observed FAHI score
during the ART phase was the end point in this analysis. Therefore, a study participant was
considered to have achieved minimally important improvement when the end point FAHI
score was greater than the threshold. Linear mixed effects regression models were fitted to
longitudinal FAHI scores to assess trends over time since ART referral, adjusting for
demographic, HIV behavioral risk and clinical factors. Separate regression models were
fitted for overall FAHI and five different sub-domains. To avoid over-adjustment bias
related to controlling for intermediate variables on the causal pathway [26], viral load and
CD4 were not included in the models (referred to hereafter as main models). Separate
analyses were conducted to assess whether CD4 and viral load were effect modifiers in the
relationship between ART and overall FAHI and five different sub-domains outcomes. All
analyses were conducted using STATA version 13 (StataCorp, College Station, TX, USA).
Results
Characteristics of ART Cohort at Enrolment
All participants (Table 1) were black South African women (n = 51) with a mean age of 25.9
years (range 18–43). Approximately 75 % were married or had a stable partnership, and
over half (54.9 %) reported having completed grades 11 or 12 of schooling. Thirty-one
women (60.8 %) had at least one child who was financially dependent, and seven (13.7 %)
disclosed being engaged in sex work. The majority of participants (82.4 %) had knowledge
of HIV transmission and over half (54.9 %) were considered to be overweight/obese based
on BMI measurement. The mean CD4 count was 488 cells/mm3 (range 229–1,358), and
median log viral load was 4.7 copies/ml (IQR 4.2–5.1) at enrollment. The median number of
days between baseline and referral for ART initiation was 638 days.
The group comparison assessment of baseline characteristics indicates that marital status (χ2
= 6.78, p = 0.03), presence of casual partners (χ2 = 7.64, p < 0.01) and educational
attainment (χ2 = 10.49, p = 0.01) were significantly associated with ART initiation status.
Lower baseline CD4 (t = 3.18, p < 0.01) and higher log viral load (p < 0.01) were detected
among the ART-cohort compared (n = 51) to non-ART cohort (n = 109).
Overall and Subscale FAHI Score Comparisons Between Established Infection and ART
Phase
Comparison of FAHI scores between pre-ART (established infection) and ART phases using
paired Wilcoxon signed-rank tests (Table 2) showed that overall (z = −3.6, p < 0.01), PWB
(z = −3.0, p < 0.01), EWB (z = −3.8, p < 0.01), and SWB (z = −2.8, p < 0.01) were
significantly higher on ART compared to the established infection phase. No significant
difference between phases was detected in FGWB and CF. The proportion of study
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participants meeting meaningful HRQoL improvements in overall, PWB, EWB, FGWB,
SWB and CF were 39, 30, 30, 20, 36 and 32 %, respectively (Table 2).
Health-Related Quality of Life Ratings Over Time from ART Referral
The adjusted linear mixed effects regression models (Table 3), similar to the Wilcoxon
signed-rank tests, showed that ART was associated with higher levels of overall HRQoL (β
= 12.31, p <0.01), and of PWB (β = 2.73, p = 0.03), EWB (β = 2.72, p = 0.03), and SWB
sub-domains (β = 3.81, p <0.01). Stable partnership, as compared to multiple partnerships,
was also a significant positive predictor of various aspects of HRQoL [overall (β = 14.13, p
= 0.03), PWB (β = 6.20, p = 0.01), FGWB (β = 4.28, p = 0.03) and CF (β = 1.88, p = 0.04)].
The assessment of the time trend variable from the same regression models indicated that
overall and FAHI sub-scale remained stable since ART referral. The assessment of the
interaction term in separate models indicated that CD4 was an effect modifier of the
relationship between ART and EWB (β = 0.81, p = 0.04), as well as CF (β = −0.48, p <0.01)
outcomes, but not in other sub-domains. The exposure to ART was an independent predictor
of (only) CF after adjusting for interaction terms (β = 3.74, p <0.01).
Discussion
Our study found an improvement in overall HRQoL, PWB, EWB, and SWB on ART and no
negative impact on FGWB and CF. Approximately one-third of participants showed
meaningful long-term HRQoL improvements from the time of ART referral. No adverse
impact of ART on HRQoL was detected.
While our findings are consistent with other quality of life studies that detected positive
treatment outcomes in physical [27–30], emotional/mental [27, 29, 31–33], and social well-
being [29, 32, 34], some studies raise concerns over potential negative consequences of
ART on HRQoL, including possible short-term adverse drug reactions [35], which may
explain the decline in well-being domains in certain studies [33, 36]. In addition, fear of
stigma and social discrimination [37–41] associated with ART treatment disclosure may
negatively influence the quality of social relationships and general well-being. While
adverse effects and stigma are major concerns in HIV treatment, medical interventions as
well as perceptions of the disease evolve over time with education and public awareness.
Our study did not detect any detrimental impact of ART, and it is possible, that newer ART
regimens are better tolerated, which may account for the lack of decline in PWB in our
study, although the role and availability of post-HIV counselling and ART clinical treatment
guidance for our participants cannot be discounted.
Notably, a South African qualitative study of ART-related stigma indicated a positive life
outlook facilitated by treatment literacy courses and treatment support groups involving
patient, peers and family members at clinics [42]. These networks provided supportive
environments and lessened the experiences of isolation, fear and stress among study
participants. Thus, the counseling and treatment advice available in the study may partially
account for observed improvements in social relations. While disclosure of ART may lower
the quality of social relations and induce stigma, based on our findings, we generally concur
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with the World Health Organization’s [43] statement that attitudes towards HIV can change,
and stigma can be reduced given that the disease is preventable and treatable with ART.
While our study did not detect ART-related improvements in FGWB and CF from the time
of ART referral, this finding should be interpreted with some caution. Cognitive decline is
known to accompany HIV progression, a finding detected in our previous investigation of
the natural history of HIV 1 subtype C infection in ART-naïve women with extensive
follow-up after acute infection [16]. In our current study, however, CF exhibited a non-
monotonic shape, indicating initial stabilization and later rebounding, a finding consistent
with a systematic review suggesting only partial improvement in neurocognitive function
due to ART [44]. Lastly, FGWB, measuring performance of normal activities and overall
feelings of well-being, (including hope and outlook for the future), remained stable from the
time of ART referral. This may signal uncertainty towards the future among those on ART,
and it justifies the need for supportive environments accompanying any ART scale-up
initiatives. The overall ART-related improvement or stabilization on HRQoL warrants
strengthening and further improvement of access to such life-saving services.
Nevertheless, the study had some limitations. Firstly, the relatively small sample of the ART
cohort warrants some caution with regards to the interpretation. In particular, the observed
association between ART and CF, may not be generalizable, requiring further studies with a
larger cohort size of patients on ART. Secondly, the study was limited by not systematically
measuring adherence to ART. While improvements in HRQoL are believed to be correlated
with treatment adherence, it is possible that there is a delayed effect. The lack of adherence
data, such as pill count, did not permit us to employ regression models to better capture
causal inference between ART and HRQoL. Despite of these limitations, our results suggest
that HRQoL among HIV-infected women either improved or stabilized on ART. Given that
we did not detect a negative impact of ART on quality of life, this study provides additional
non-biomedical support to early treatment strategies.
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